Table 3.
Frequency of the adverse effects in each group.
| Adverse Effects | Placebo (Sessions= 23) | Combined Interventions (Sessions = 23) | iTBS-only (Sessions = 23) | tDCS-only (Sessions = 24) | p-value |
|---|---|---|---|---|---|
| Headache | 0 (0%) | 13 (10.9%) | 10 (8.7%) | 0 (0%) | 0.02 |
| Neck Pain | 2 (1.7%) | 0 (0%) | 3 (2.6%) | 4 (3.3%) | 0.75 |
| Local Pain | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | - |
| Itching | 29 (25.2%) | 31 (25.8%) | 28 (24.3%) | 31 (25.8%) | 0.99 |
| Tingling | 29 (25.2%) | 31 (25.8%) | 28 (24.3%) | 31 (25.8%) | 0.99 |
| Burning | 2 (1.7%) | 8 (6.7%) | 2 (1.7%) | 6 (5.2%) | 0.47 |
| Skin Redness | 23 (20%) | 42 (35%) | 20 (17.4%) | 45 (37.5%) | < 0.001 |
| Somnolence | 16 (13.9%) | 12 (10%) | 10 (8.7%) | 25 (20.8%) | 0.24 |
| Cognition Changes | 3 (2.6%) | 2 (1.7%) | 0 (0%) | 4 (3.3%) | 0.75 |
| Mood Changes | 3 (2.6%) | 5 (4.2%) | 3 (2.6%) | 6 (5.2%) | 0.92 |
| Fatigue | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | - |
| Nausea | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | - |
| Facial Contraction | 8 (6.9%) | 23 (19.2%) | 29 (25.2%) | 6 (5.2%) | 0.01 |
| Dizziness | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | - |
iTBS: Intermittent theta-burst stimulation; tDCS: transcranial direct current stimulation.